EPHA2 and glioblastoma: In preclinical models, CAR T cells have been designed to target CSC-associated antigens, such as CD133 in glioblastoma [97], CSPG4 in multiple cancer types [79], EGFRvIII [80], IL13Rα2 [81] and EphA2 in gliomas [98,99], SSEA1 in medulloblastoma, glioblastoma and neuroendocrine tumors [100], HER2 in osteosarcoma [101], GD2 and TEM8 in breast tumor [102,103], EpCAM and PSCA in prostate cancer [82,104].